Bimatoprost Brown & Burk
Preservative-free prostaglandin analogue eye drops for glaucoma and ocular hypertension
Bimatoprost Brown & Burk is a preservative-free ophthalmic solution containing bimatoprost 0.3 mg/ml, supplied in single-dose containers. It is a prostaglandin analogue used to reduce elevated intraocular pressure (IOP) in adults with open-angle glaucoma or ocular hypertension. This formulation is particularly suitable for patients who are sensitive to preservatives commonly found in multi-dose eye drop bottles. Applied once daily in the evening, bimatoprost reduces IOP by approximately 25–35% from baseline levels.
Quick Facts
Key Takeaways
- Bimatoprost Brown & Burk is a preservative-free eye drop that reduces intraocular pressure in glaucoma and ocular hypertension by enhancing aqueous humor outflow.
- Applied once daily in the evening to the affected eye(s), this formulation comes in single-dose containers that should be discarded after each use.
- Common side effects include eye redness, itching, eyelash growth changes, and potential permanent iris color darkening in patients with mixed-color irises.
- The preservative-free formulation is better tolerated on the ocular surface, making it ideal for patients sensitive to benzalkonium chloride or using multiple eye drops.
- Regular ophthalmological monitoring is essential to track IOP levels, check for iris pigmentation changes, and assess treatment effectiveness.
What Is Bimatoprost Brown & Burk and What Is It Used For?
Quick Answer: Bimatoprost Brown & Burk is a prescription eye drop containing the prostaglandin analogue bimatoprost (0.3 mg/ml) in preservative-free single-dose containers. It is used to lower elevated intraocular pressure in adults with open-angle glaucoma or ocular hypertension.
Bimatoprost Brown & Burk belongs to a class of medications known as prostaglandin analogues, which are considered the first-line pharmacological treatment for open-angle glaucoma and ocular hypertension worldwide. Open-angle glaucoma is a progressive optic neuropathy characterized by damage to the optic nerve, often associated with elevated intraocular pressure (IOP). Left untreated, it can lead to irreversible vision loss and blindness. According to the World Health Organization (WHO), glaucoma is the second leading cause of blindness globally, affecting an estimated 80 million people worldwide.
The active ingredient, bimatoprost, is a synthetic prostamide analogue that works by enhancing the natural drainage pathways of the eye. It increases the outflow of aqueous humor—the clear fluid that fills the front of the eye—through both the trabecular meshwork (the conventional outflow pathway) and the uveoscleral route (the unconventional outflow pathway). This dual mechanism of action results in a significant and sustained reduction of IOP, typically lowering pressure by 25–35% from baseline levels.
Ocular hypertension refers to elevated IOP without optic nerve damage or visual field loss. While not all patients with ocular hypertension develop glaucoma, treating elevated IOP has been shown in major clinical trials, including the Ocular Hypertension Treatment Study (OHTS) and the European Glaucoma Prevention Study (EGPS), to significantly reduce the risk of progression to glaucoma. Bimatoprost is among the most effective IOP-lowering agents available, making it a preferred choice for both conditions.
What distinguishes Bimatoprost Brown & Burk from many other bimatoprost formulations is its preservative-free single-dose container presentation. Traditional multi-dose eye drop bottles typically contain benzalkonium chloride (BAK) as a preservative, which has been shown to cause ocular surface toxicity, including disruption of the tear film, corneal epithelial cell damage, and worsening of dry eye disease with chronic use. The preservative-free formulation is therefore particularly beneficial for patients with pre-existing ocular surface disease, those who wear contact lenses, and individuals using multiple topical eye medications concurrently.
Major clinical trials, including the Bimatoprost Study Groups I and II, demonstrated that bimatoprost 0.03% provides IOP reduction comparable to or greater than timolol 0.5% (the gold-standard comparator), with mean IOP reductions of 7–9 mmHg from baseline. The European Glaucoma Society (EGS) and the American Academy of Ophthalmology (AAO) recommend prostaglandin analogues as first-line therapy for open-angle glaucoma based on their efficacy, once-daily dosing, and favorable systemic safety profile.
What Should You Know Before Taking Bimatoprost Brown & Burk?
Quick Answer: Before using Bimatoprost Brown & Burk, inform your doctor about any eye conditions, allergies, pregnancy or breastfeeding status, and all other medications you are using. This medicine may cause permanent changes to eye color, eyelash appearance, and periorbital skin.
Contraindications
Bimatoprost Brown & Burk should not be used if you have a known hypersensitivity to bimatoprost or any of the excipients in the formulation. Although true allergic reactions to bimatoprost are uncommon, patients who have experienced allergic conjunctivitis or contact dermatitis with previous prostaglandin analogue use should exercise caution. The excipients in the single-dose formulation include sodium chloride, disodium hydrogen phosphate heptahydrate, citric acid monohydrate, and purified water.
Patients with active intraocular inflammation (such as iritis or uveitis) should use bimatoprost with particular caution, as prostaglandin analogues can exacerbate inflammatory processes within the eye. Additionally, patients who have undergone certain types of ocular surgery, particularly those with compromised posterior lens capsule or risk factors for cystoid macular edema (including aphakia, pseudophakia with a torn posterior lens capsule, or known risk factors for macular edema), should be carefully monitored during treatment.
Warnings and Precautions
Several important warnings apply to the use of bimatoprost eye drops. Perhaps the most distinctive is the potential for iris pigmentation changes. Bimatoprost may gradually increase the brown pigmentation of the iris due to increased melanin production within the iris stromal melanocytes. This effect is most commonly observed in patients with mixed-color irises (blue-brown, grey-brown, yellow-brown, or green-brown) and appears to be less common in patients with uniformly colored irises (blue, grey, green, or brown). The pigmentation change is generally slow and may not be noticeable for months to years. Importantly, this change may be permanent and may become more noticeable if only one eye is treated.
Other notable warnings and precautions include:
- Eyelash changes: Bimatoprost can cause changes in eyelashes and vellus hair in the treated eye, including increased length, thickness, pigmentation, and number of lashes. These changes are usually reversible upon discontinuation of treatment.
- Periorbital skin changes: Darkening of the eyelid skin (periorbital hyperpigmentation) may occur. Fat atrophy around the eye (periorbital lipodystrophy or prostaglandin-associated periorbitopathy, PAP) has also been reported, which can cause a sunken appearance of the eye.
- Contact lenses: If you wear contact lenses, remove them before applying the eye drops and wait at least 15 minutes before reinserting them. The preservative-free formulation of Bimatoprost Brown & Burk, however, is less likely to damage contact lenses compared to BAK-containing formulations.
- Herpetic keratitis: Prostaglandin analogues should be used with caution in patients with a history of herpes simplex keratitis, as they may reactivate the virus.
- Bacterial keratitis: Although single-dose containers minimize contamination risk, patients should still practice proper hygiene when handling and applying eye drops.
Pregnancy and Breastfeeding
Bimatoprost Brown & Burk should not be used during pregnancy unless clearly necessary and the potential benefit justifies the potential risk to the fetus. Animal reproductive studies have shown adverse effects at systemic doses significantly higher than those achieved through ophthalmic administration. However, there are limited data on the use of bimatoprost in pregnant women. Women of childbearing potential should use effective contraception during treatment.
It is not known whether bimatoprost is excreted in human breast milk, although it has been detected in the milk of lactating rats. A decision should be made whether to discontinue breastfeeding or to discontinue treatment, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. If bimatoprost is deemed essential, the use of nasolacrimal occlusion (pressing on the inner corner of the eye after instillation) can help minimize systemic absorption.
If you are pregnant, planning to become pregnant, or breastfeeding, consult your ophthalmologist before using Bimatoprost Brown & Burk. Do not start, stop, or change the dosage of this medication without your doctor's guidance. Report any unusual eye changes, including changes in iris color, eyelash appearance, or periorbital skin darkening, to your healthcare provider promptly.
How Does Bimatoprost Brown & Burk Interact with Other Drugs?
Quick Answer: Bimatoprost has limited systemic absorption when applied as eye drops, so significant systemic drug interactions are rare. However, concomitant use with other prostaglandin analogues is not recommended, and timing should be coordinated when using multiple eye drops.
Because bimatoprost is administered topically to the eye and undergoes relatively limited systemic absorption, clinically significant drug interactions are uncommon compared to systemically administered medications. However, several interactions are worth noting for safe and effective use of this medicine.
The most important interaction consideration is with other ophthalmic prostaglandin analogues. Using two prostaglandin analogues concurrently (such as bimatoprost with latanoprost or travoprost) is not recommended, as this may paradoxically reduce the IOP-lowering effect rather than enhance it. This is thought to be due to receptor desensitization or competitive binding at the prostaglandin receptor level. If a patient requires additional IOP-lowering therapy beyond bimatoprost, medications from different classes (such as beta-blockers, carbonic anhydrase inhibitors, or alpha-agonists) should be used instead.
When multiple eye drops are prescribed, it is important to allow adequate time between instillations. A minimum interval of 5 minutes is recommended between different eye drop medications to prevent washout of the first drop and ensure adequate absorption of each drug. This timing is especially important when combining bimatoprost with other antiglaucoma agents.
Major Interactions
| Interacting Drug | Type | Effect | Recommendation |
|---|---|---|---|
| Other prostaglandin analogues (latanoprost, travoprost, tafluprost) | Pharmacodynamic | May reduce IOP-lowering efficacy due to receptor desensitization | Do not use concurrently; switch between agents if needed |
| NSAIDs (ophthalmic, e.g., ketorolac, diclofenac eye drops) | Pharmacodynamic | NSAIDs may reduce the IOP-lowering effect of prostaglandin analogues | Monitor IOP closely if co-administered; consider alternative anti-inflammatory agents |
Minor Interactions
| Interacting Drug | Type | Effect | Recommendation |
|---|---|---|---|
| Timolol (beta-blocker eye drops) | Additive | Additive IOP-lowering effect; well-established combination | May be used together; allow 5-minute interval between drops |
| Brimonidine (alpha-agonist eye drops) | Additive | Additive IOP-lowering effect through different mechanisms | May be used together; allow 5-minute interval between drops |
| Dorzolamide/brinzolamide (carbonic anhydrase inhibitors) | Additive | Additive IOP-lowering effect; complementary mechanisms | May be used together; allow 5-minute interval between drops |
| Artificial tears / lubricant eye drops | Dilution | May dilute bimatoprost if applied too close together | Wait at least 5–15 minutes between applications |
If you are using more than one type of eye drop, always wait at least 5 minutes between different medications. Apply bimatoprost last in the evening dosing sequence when possible, as it is best applied at bedtime. If you also use an eye ointment, apply the ointment last, as ointments can interfere with the absorption of eye drops.
What Is the Correct Dosage of Bimatoprost Brown & Burk?
Quick Answer: The recommended dose is one drop in the affected eye(s) once daily, administered in the evening. Do not exceed the recommended dose, as more frequent application may reduce the IOP-lowering effect.
The dosage of Bimatoprost Brown & Burk is straightforward, reflecting one of the key advantages of prostaglandin analogues as a class—once-daily dosing. Clinical studies have consistently demonstrated that once-daily dosing in the evening provides optimal IOP reduction throughout the 24-hour period. The peak IOP-lowering effect typically occurs approximately 8–12 hours after instillation, aligning with the morning hours when IOP tends to be highest.
Adults
Standard Adult Dosage
Dose: One drop of Bimatoprost Brown & Burk 0.3 mg/ml in the affected eye(s).
Frequency: Once daily, preferably in the evening.
Duration: Continuous long-term therapy as directed by your ophthalmologist. Glaucoma treatment is typically lifelong.
Important: Do not exceed once-daily dosing. Studies have shown that more frequent instillation can paradoxically reduce the IOP-lowering effect. If a dose is missed, do not double the next dose—simply resume the normal schedule the following evening.
Elderly
Elderly Patients (65 Years and Older)
No dose adjustment is required for elderly patients. The standard dose of one drop once daily in the evening applies. However, elderly patients may be more susceptible to periorbital changes (fat atrophy, skin darkening) and may require more frequent monitoring. Given that glaucoma prevalence increases significantly with age, elderly patients represent a large proportion of bimatoprost users.
Children and Adolescents
Pediatric Use
Bimatoprost Brown & Burk is not recommended for use in children and adolescents under 18 years of age due to insufficient data on safety and efficacy in this population. Pediatric glaucoma is a distinct condition that typically requires specialized management, often including surgical intervention. If ophthalmic prostaglandin analogues are considered for pediatric use, this should only be under the close supervision of a pediatric ophthalmologist.
Missed Dose
If you forget to apply your eye drops at the usual time, apply them as soon as you remember on the same day. If you do not remember until the following day, skip the missed dose and continue with your regular schedule the next evening. Do not apply a double dose to make up for a forgotten dose. Missing a single dose will not significantly affect your IOP control, but consistent daily use is important for optimal long-term management of your condition.
Overdose
Overdose through ophthalmic administration is unlikely to cause serious systemic toxicity due to the small volume of the eye drops and limited systemic absorption. If more drops than recommended are accidentally applied to the eye, the eye may become irritated or red. Rinse the eye with clean water or sterile saline solution if necessary. If the single-dose container solution is accidentally ingested, symptoms may include nausea, vomiting, or abdominal discomfort. In the event of accidental ingestion, seek medical advice. Treatment would be symptomatic and supportive, as there is no specific antidote for bimatoprost.
Proper technique is essential for effective treatment: (1) Wash your hands thoroughly. (2) Separate one single-dose container from the strip and twist off the top. (3) Tilt your head back and gently pull down the lower eyelid. (4) Squeeze one drop into the conjunctival sac, avoiding contact between the container tip and the eye. (5) Close your eye gently and apply nasolacrimal occlusion (press your finger against the inner corner of the eye near the nose) for 1–2 minutes. (6) Discard the single-dose container immediately after use, even if solution remains.
What Are the Side Effects of Bimatoprost Brown & Burk?
Quick Answer: The most common side effects are conjunctival hyperemia (eye redness), eye pruritus (itching), eyelash growth changes, and eye irritation. Most side effects are mild and ocular in nature. Serious systemic side effects are rare due to limited systemic absorption.
Like all medicines, Bimatoprost Brown & Burk can cause side effects, although not everybody gets them. The majority of side effects associated with bimatoprost are ocular (related to the eye) and are generally mild to moderate in severity. Many of these effects tend to diminish with continued use as the eye adapts to the medication. The preservative-free formulation may reduce the incidence and severity of ocular surface irritation compared to preserved formulations.
The side effect profile of bimatoprost has been well characterized through extensive clinical trials and post-marketing surveillance involving thousands of patients worldwide. The following classification uses the standard frequency categories based on clinical trial data and spontaneous adverse reaction reports.
Very Common
May affect more than 1 in 10 people
- Conjunctival hyperemia (redness of the eye) — the most frequently reported side effect, occurring in up to 40–50% of patients. This is usually mild and tends to decrease with continued use
Common
May affect up to 1 in 10 people
- Eye pruritus (itching)
- Eyelash growth changes (increased length, thickness, and pigmentation)
- Eye irritation and burning sensation
- Periorbital skin hyperpigmentation (darkening of skin around the eye)
- Dry eyes
- Erythema of the eyelid (redness)
- Foreign body sensation
- Ocular pain or discomfort
Uncommon
May affect up to 1 in 100 people
- Iris hyperpigmentation (permanent change in eye color)
- Photophobia (increased sensitivity to light)
- Allergic conjunctivitis
- Asthenopia (eye strain or fatigue)
- Blepharitis (inflammation of the eyelid margin)
- Visual disturbance including blurred vision
- Increased lacrimation (watery eyes)
- Periorbital fat atrophy (deepening of the eyelid sulcus)
- Headache
Rare
May affect up to 1 in 1,000 people
- Cystoid macular edema (swelling in the central retina)
- Iritis / uveitis (intraocular inflammation)
- Enophthalmos (sunken appearance of the eye)
- Dizziness
- Hypertrichosis (abnormal hair growth in the periorbital area)
- Skin discoloration in areas distant from the application site
- Asthma exacerbation (in predisposed individuals)
Contact your ophthalmologist immediately if you experience: sudden vision loss or significant visual changes, severe eye pain, signs of eye infection (purulent discharge, significant swelling), severe allergic reaction (swelling of face, lips, throat, or difficulty breathing), or symptoms of cystoid macular edema (central vision distortion or blurring). If you notice a gradual change in the color of your treated eye(s), inform your doctor at your next appointment—while this is not an emergency, it should be documented and discussed.
It is important to note that the preservative-free formulation of Bimatoprost Brown & Burk may offer advantages in terms of ocular surface tolerability compared to preserved bimatoprost formulations. Long-term studies have shown that BAK-containing eye drops can cause progressive ocular surface disease, including meibomian gland dysfunction, conjunctival inflammation, and corneal toxicity. Switching to a preservative-free formulation has been shown to improve signs and symptoms of ocular surface disease in patients previously using preserved eye drops.
How Should You Store Bimatoprost Brown & Burk?
Quick Answer: Store below 25°C in the original packaging to protect from light. Single-dose containers should be used immediately after opening and any remaining solution discarded. Keep out of reach of children.
Proper storage of Bimatoprost Brown & Burk is important to maintain the stability and sterility of the medication. The single-dose container format provides inherent advantages in terms of sterility, as each container is sealed and sterile until opened, eliminating the risk of microbial contamination that can occur with multi-dose bottles over time.
The following storage conditions should be observed:
- Temperature: Store below 25°C (77°F). Do not freeze. If the solution has been frozen, do not use it.
- Light protection: Keep the single-dose containers in the original foil pouch to protect from light. Bimatoprost may degrade when exposed to prolonged direct light.
- After opening: Use the single-dose container immediately after opening. Discard any unused solution remaining in the container. Do not store opened containers for later use.
- Once the foil pouch is opened: Use all single-dose containers within 30 days. Note the date you open the foil pouch and discard any remaining unused containers after 30 days.
- Keep out of reach: Store out of the sight and reach of children.
- Expiry date: Do not use this medicine after the expiry date stated on the carton and single-dose container. The expiry date refers to the last day of that month.
Do not dispose of medicines via wastewater or household waste. Ask your pharmacist about how to dispose of medicines you no longer use. Proper disposal helps protect the environment and prevents accidental exposure.
What Does Bimatoprost Brown & Burk Contain?
Quick Answer: Each ml of solution contains 0.3 mg of bimatoprost as the active ingredient. The solution is preservative-free, with excipients including sodium chloride, phosphate buffers, citric acid, hydrochloric acid/sodium hydroxide for pH adjustment, and purified water.
Understanding the composition of your medication can help you identify potential allergens and understand how the formulation works. Bimatoprost Brown & Burk is specifically formulated as a preservative-free solution, which is an important distinction from many other ophthalmic preparations.
Active Ingredient
The active ingredient is bimatoprost, present at a concentration of 0.3 mg/ml (equivalent to 0.03%). Bimatoprost is a synthetic prostamide analogue with the chemical name (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-5-heptenamide. It has a molecular weight of 415.57 g/mol and appears as a white to off-white powder that is soluble in ethanol and slightly soluble in water.
Other Ingredients (Excipients)
The excipients in the preservative-free formulation include:
- Sodium chloride: Used to adjust the tonicity (osmolality) of the solution to match that of natural tears, ensuring comfort upon instillation.
- Disodium hydrogen phosphate heptahydrate: Acts as a buffer to maintain the pH of the solution within a range compatible with the eye.
- Citric acid monohydrate: Also acts as a buffering agent to help maintain pH stability.
- Hydrochloric acid and/or sodium hydroxide: Used for final pH adjustment to ensure the solution is within the acceptable pH range for ophthalmic use (typically pH 6.5–7.5).
- Purified water: The vehicle for the solution.
Notably absent from this formulation is benzalkonium chloride (BAK), which is the most commonly used preservative in ophthalmic preparations. BAK is a quaternary ammonium compound with detergent properties that can disrupt the lipid layer of the tear film, cause direct toxicity to corneal and conjunctival epithelial cells, and contribute to inflammatory changes on the ocular surface with chronic use. The absence of BAK in Bimatoprost Brown & Burk makes it a preferred choice for long-term therapy and for patients with compromised ocular surfaces.
Frequently Asked Questions
Bimatoprost Brown & Burk is used to reduce elevated intraocular pressure (IOP) in adults with open-angle glaucoma or ocular hypertension. It contains bimatoprost 0.3 mg/ml in preservative-free single-dose containers. By lowering IOP, it helps prevent damage to the optic nerve that can lead to vision loss. It is applied as one drop in the affected eye(s) once daily in the evening.
Yes, bimatoprost can gradually increase brown pigmentation of the iris, and this change may be permanent. It is most commonly seen in patients with mixed-color irises (blue-brown, grey-brown, yellow-brown, or green-brown). The color change occurs because bimatoprost stimulates melanin production in the iris melanocytes. If only one eye is treated, there may be a noticeable difference in eye color between the two eyes. This effect is not associated with any harmful consequences, but you should discuss it with your ophthalmologist before starting treatment.
Traditional multi-dose eye drops contain preservatives like benzalkonium chloride (BAK) to prevent microbial growth. However, BAK can damage the ocular surface with long-term use, causing dry eyes, corneal toxicity, and conjunctival inflammation. Since glaucoma treatment is typically lifelong, preservative-free formulations like Bimatoprost Brown & Burk are particularly important to maintain the health of the eye surface over many years of treatment. They are especially beneficial for patients already experiencing dry eyes, those using multiple eye drops, or contact lens wearers.
If you forget your evening dose, apply it as soon as you remember on the same day. If you do not remember until the next day, skip the missed dose and continue with your regular schedule the following evening. Never apply a double dose. Missing a single dose occasionally will not significantly affect your treatment outcome, but consistent daily use is important for optimal IOP control. If you frequently forget doses, consider setting a daily reminder or alarm.
Yes, but you should remove your contact lenses before applying the eye drops. Although Bimatoprost Brown & Burk is preservative-free (which is less likely to damage lenses), it is still recommended to wait at least 15 minutes after applying the drops before reinserting contact lenses. This allows the medication to be fully absorbed and avoids any potential interaction between the solution and the lens material. Since bimatoprost is applied once daily in the evening, many patients find it convenient to apply the drops after removing their contact lenses for the night.
Bimatoprost begins to lower intraocular pressure within approximately 4 hours of the first dose, with the maximum IOP-lowering effect reached after approximately 8–12 hours. However, the full therapeutic effect may take several weeks of consistent daily use to stabilize. Your ophthalmologist will typically schedule a follow-up appointment 2–4 weeks after starting treatment to assess the IOP response and determine if the medication is providing adequate pressure reduction. Do not stop using the medication early, even if you feel well, as glaucoma is typically asymptomatic until significant vision loss has occurred.
References
This article is based on the following peer-reviewed sources, regulatory documents, and clinical guidelines:
- European Medicines Agency (EMA). Bimatoprost — Summary of Product Characteristics (SmPC). European Public Assessment Report. Available at: www.ema.europa.eu.
- European Glaucoma Society (EGS). Terminology and Guidelines for Glaucoma, 5th Edition (2020). European Glaucoma Society.
- American Academy of Ophthalmology (AAO). Preferred Practice Pattern: Primary Open-Angle Glaucoma (2020). Ophthalmology.
- NICE Clinical Guideline [NG81]. Glaucoma: diagnosis and management (2017, updated 2022). National Institute for Health and Care Excellence.
- Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713. doi:10.1001/archopht.120.6.701.
- Brandt JD, Cantor LB, Katz LJ, et al. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008;17(3):211–216.
- Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312–334. doi:10.1016/j.preteyeres.2010.03.001.
- World Health Organization (WHO). World Report on Vision (2019). Available at: www.who.int.
- British National Formulary (BNF). Bimatoprost — Prescribing Information. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk.
- Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. doi:10.1016/j.ophtha.2014.05.013.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising board-certified physicians specializing in ophthalmology, pharmacology, and evidence-based medicine. All content is developed according to the GRADE evidence framework and follows international guidelines from the EMA, FDA, WHO, and NICE.
iMedic Medical Editorial Team — specialists in ophthalmology and clinical pharmacology with extensive experience in medical information development.
iMedic Medical Review Board — independent panel of medical experts who verify clinical accuracy, evidence quality, and adherence to international guidelines.
Conflict of Interest Statement: The iMedic editorial team has no financial relationships with pharmaceutical companies. All content is independently funded and produced without commercial sponsorship or influence.
Last Medical Review: